Schering-Plough PEG-Intron
Executive Summary
Schering-Plough plans fall launch of PEG-Intron (peginterferon alfa-2b) in combination with Rebetol (ribavirin) for treatment of chronic hepatitis C following Aug. 7 supplemental approval. Rebetol was approved July 26 as a separate product to be used with Intron A and was previously approved as part of the ribavirin/Intron A combination therapy Rebetron (1"The Pink Sheet" July 30, p. 19)